Research
Recent Publications
A Receptor Story: Insulin Resistance Pathophysiology and Physiologic Insulin Resensitization’s Role as a Treatment Modality
Reversal of Diabetic Retinopathy in two Patients Following the use of Physiologic Insulin Resensitization
A Receptor Story: Insulin Resistance Pathophysiology and Physiologic Insulin Resensitization’s Role as a Treatment Modality
Reversal of Diabetic Retinopathy in two Patients Following the use of Physiologic Insulin Resensitization
Other Publications
“Economic Costs of Diabetes in the U.S. 2017” (Published online in Diabetes Care Mar, 2018)
Per Brian Loveridge, MD; “Diabetes represents the most expensive medical condition in America. The prevalence continues to rise, with one out of two adults having either diabetes or pre-diabetes. Greater focus and attention is needed to address the complications of this epidemic that plagues both the U.S., and the world at large. We want to be a part of the solution with our physiologic insulin treatments.”
“ACP Recommends Less Intensive Glycemic Control Targets for Type 2 Diabetes” (Ann Internal Medicine, Mar 2018)
Per Brian Loveridge, MD; “Detailed scientific exploration of how impaired insulin production leads to a breakdown in carbohydrate metabolism. In pre-diabetes, the body tries to overcome progressive insulin resistance by producing higher levels of insulin. Unfortunately, this creates a “toxic” environment for these receptors. With increasing insulin “resistance,” a patient goes from impaired glucose metabolism to type 2 diabetes. We aim to restore the natural physiology toward improved glycemic control.”